{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:53:31Z","timestamp":1791039211630,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.patbio.2010.12.005","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T21:01:10Z","timestamp":1351198870000},"page":"e27-e31","source":"Crossref","is-referenced-by-count":7,"title":["Phase I \u2013 II study to assess the feasibility and activity of the triple combination of 5-fluorouracil\/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study"],"prefix":"10.1016","volume":"61","author":[{"given":"C.","family":"Focan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Graas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Longr\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Focan-Henrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Demolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Moeneclaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2010.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2010.12.005_bib0010","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"16","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2010.12.005_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2010.12.005_bib0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl Med"},{"key":"10.1016\/j.patbio.2010.12.005_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"Folfiri followed by Folfox 6 or the reverse sequence in advanced colorectal cancer: a randomized Gercor study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0163-7258(95)00009-6","article-title":"Circadian rhythms and cancer chronotherapy","volume":"67","author":"Focan","year":"1995","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.patbio.2010.12.005_bib0045","series-title":"Chronotherapeutics","first-page":"235","article-title":"Rhythms of cancer chemotherapy","author":"Focan","year":"2003"},{"key":"10.1016\/j.patbio.2010.12.005_bib0050","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","article-title":"Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multi-institutional trial","volume":"86","author":"L\u00e9vi","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.patbio.2010.12.005_bib0055","first-page":"885","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as fist-line treatment of metastatic colorectal cancer. Classic Papers and Current Comments","volume":"6","author":"Giacchetti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0060","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2006.06.1440","volume":"24","author":"Giacchetti","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet"},{"issue":"9\u201310","key":"10.1016\/j.patbio.2010.12.005_bib0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.addr.2006.11.001","article-title":"Implications of circadian clocks for the rhythmic delivery of cancer therapeutics","volume":"59","author":"L\u00e9vi","year":"2007","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.patbio.2010.12.005_bib0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0959-8049(99)00282-8","article-title":"Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial","volume":"36","author":"Focan","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.patbio.2010.12.005_bib0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.patbio.2004.12.029","article-title":"Chronotherapie associant le 5-fluorouracile, l\u2019acide folinique, et le carboplatine en premi\u00e8re ligne th\u00e9rapeutique dans le cancer colorectal m\u00e9tastatique. Une \u00e9tude de phase 2","volume":"53","author":"Focan","year":"2005","journal-title":"Pathol Biol"},{"key":"10.1016\/j.patbio.2010.12.005_bib0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hon.2900080108","article-title":"The myelotoxicity of carboplatin is influenced by the time of its administration","volume":"8","author":"Kerr","year":"1990","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.patbio.2010.12.005_bib0090","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/sj.bjc.6601382","article-title":"A phase II study of irinotecan plus chronomodulated oxaliplatin, 5 flouoruracil and folinic acid in advanced colorectal cancer patients","volume":"89","author":"Garufi","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.patbio.2010.12.005_bib0095","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdh470","article-title":"First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil\/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule","volume":"15","author":"Masi","year":"2004","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.patbio.2010.12.005_bib0100","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.patbio.2010.12.005_bib0105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.bjc.6600168","article-title":"Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma","volume":"86","author":"Granda","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.patbio.2010.12.005_bib0110","first-page":"117b","article-title":"Randomized multicenter trial of irinotecan chronomodulated versus standard infusion in patients with metastatic colorectal cancer","volume":"20","author":"Giacchetti","year":"2001","journal-title":"Proc ASCO"},{"key":"10.1016\/j.patbio.2010.12.005_bib0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.patbio.2004.12.027","article-title":"\u00c9tude de faisabilit\u00e9 (Phase I-II) d\u2019une quadruple combinaison associant le 5-fluorouracile, l\u2019acide folinique et le carboplatine \u00e0 de l\u2019irinotecan administr\u00e9s en infusion chronomodul\u00e9e pour le traitement du cancer colorectal avanc\u00e9","volume":"53","author":"Focan","year":"2005","journal-title":"Pathol Biol"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811410001598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811410001598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T22:21:46Z","timestamp":1542666106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811410001598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0369811410001598"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2010.12.005","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}